Chapter 3: Pharmacodynamics — Module 4: Signal Transduction, Receptor Superfamilies and Downstream Pharmacodynamics
1. A patient with chronic heart failure is prescribed carvedilol. The cardiology team explains that in heart failure, the beta1-adrenergic receptors in the failing heart are already substantially downregulated before carvedilol is initiated. Which of the following best explains the mechanism of this pre-existing downregulation?
A) Chronic volume overload in heart failure produces mechanical stretching of the sinoatrial node that directly internalizes beta1 receptors through a mechanosensitive endocytosis pathway independent of catecholamine signaling
B) Diuretic therapy in heart failure reduces plasma volume, lowering the effective delivery of norepinephrine to cardiac beta1 receptors and triggering compensatory receptor downregulation in response to reduced agonist stimulation
C) Elevated atrial natriuretic peptide in heart failure directly antagonizes cAMP production downstream of beta1 receptor activation, producing a pharmacodynamic downregulation of the entire Gs-cAMP signaling cascade including receptor density
D) Chronic high catecholamine levels in heart failure produce sustained beta1-receptor activation, driving GRK-mediated receptor phosphorylation, beta-arrestin recruitment, and clathrin-mediated receptor internalization; the chronically elevated sympathetic tone that the failing heart generates as a compensatory mechanism simultaneously depletes receptor density through this desensitization pathway, reducing the heart's capacity to respond to further adrenergic stimulation
E) The reduced ejection fraction in heart failure produces a compensatory increase in beta-receptor sensitivity through upregulation of Gs protein coupling efficiency, not downregulation; carvedilol is prescribed to counteract this hypersensitivity
ANSWER: D
Rationale:
In chronic heart failure, the failing heart generates compensatory neurohormonal activation including sustained elevation of circulating catecholamines (norepinephrine and epinephrine) from the sympathetic nervous system. These chronically elevated catecholamines continuously stimulate cardiac beta1-adrenergic receptors, driving sustained Gs-cAMP signaling. The cellular response to chronic agonist exposure is homologous desensitization through the GRK/beta-arrestin pathway: GRKs phosphorylate the agonist-occupied beta1 receptor, beta-arrestin binds the phosphorylated receptor and uncouples it from Gs, and the receptor is internalized via clathrin-mediated endocytosis. With chronic exposure, a proportion of internalized receptors are targeted for lysosomal degradation rather than recycling, reducing total receptor density (downregulation). The failing heart therefore has markedly reduced beta1-receptor density -- studies show reductions of 50-70% compared to normal myocardium. This downregulation underlies the blunted inotropic and chronotropic response to catecholamines in heart failure. Carvedilol (a non-selective beta-blocker with alpha1-blocking activity) is used long-term to reduce chronic catecholamine-driven receptor loss and allow receptor upregulation, improving the heart's adrenergic responsiveness over weeks to months.
Option A: Option A is incorrect -- mechanical stretch activates various signaling pathways but does not directly internalize beta1 receptors through a mechanosensitive endocytosis pathway independent of catecholamines; the primary mechanism is catecholamine-driven GRK/beta-arrestin.
Option B: Option B is incorrect -- diuretics reduce volume overload but do not cause receptor downregulation through reduced agonist delivery; beta1 downregulation in heart failure is driven by excessive catecholamine stimulation, not reduced stimulation.
Option C: Option C is incorrect -- ANP (atrial natriuretic peptide) activates particulate guanylyl cyclase (GC-A receptor), producing cGMP; while cGMP can modulate cAMP signaling, ANP does not directly cause beta1 receptor downregulation.
Option E: Option E is incorrect -- beta1 receptor density and Gs coupling efficiency are reduced (not increased) in heart failure; this is one of the central pharmacodynamic features of the failing heart.
2. A patient with anxiety disorder is prescribed diazepam 5 mg twice daily. A colleague proposes switching her to phenobarbital for what they describe as "equivalent GABA-A enhancement." A clinical pharmacologist objects on safety grounds. Which of the following best explains the pharmacodynamic basis for the safety concern?
A) Unlike diazepam, which requires GABA to produce chloride channel opening and therefore has an intrinsic ceiling on CNS depression, phenobarbital can directly open GABA-A chloride channels in the absence of GABA at supratherapeutic concentrations -- this removes the safety ceiling that GABA-dependence provides and explains why phenobarbital overdose can cause respiratory depression and death while benzodiazepine overdose alone rarely does
B) Phenobarbital is a weaker GABA-A modulator than diazepam at equivalent doses -- it produces less chloride conductance enhancement than diazepam and would provide inadequate anxiolytic coverage rather than equivalent GABA-A enhancement
C) Phenobarbital binds the same benzodiazepine site as diazepam but with lower affinity -- the faster dissociation rate produces more fluctuation in GABA-A receptor occupancy and greater CNS toxicity risk during trough periods
D) Phenobarbital activates GABA-A by increasing channel opening frequency through the same mechanism as diazepam -- the safety concern is purely pharmacokinetic, reflecting phenobarbital's very long half-life (80-120 hours) and risk of accumulation rather than any pharmacodynamic difference at the receptor
E) Phenobarbital produces direct GABA-A agonism at a lower receptor occupancy threshold than diazepam -- it achieves maximum chloride conductance at receptor occupancy levels that diazepam cannot reach, producing GABA-A overactivation rather than equivalent modulation
ANSWER: A
Rationale:
The pharmacodynamic safety distinction between benzodiazepines and barbiturates is one of the most clinically important receptor-level differences in pharmacology. Diazepam (and all benzodiazepines) are positive allosteric modulators that enhance GABA-A function in a GABA-dependent manner -- they increase the frequency of chloride channel opening events but only in the presence of GABA. When ambient GABA is depleted or receptor GABA-responsiveness reaches saturation, benzodiazepines cannot produce further CNS depression. This GABA-dependence provides an inherent safety ceiling. Phenobarbital binds transmembrane sites on the GABA-A receptor and increases the duration of channel opening at therapeutic concentrations -- also requiring GABA at these levels. However, at supratherapeutic concentrations, phenobarbital can directly open GABA-A chloride channels in the complete absence of GABA. This eliminates the safety ceiling and is the pharmacodynamic basis for phenobarbital's capacity to cause fatal respiratory depression in overdose. In clinical practice, isolated benzodiazepine overdose is very rarely fatal; phenobarbital overdose carries significant mortality without intensive supportive care. This pharmacodynamic difference -- not any pharmacokinetic difference -- is the core safety concern with the proposed switch.
Option B: Option B is incorrect -- phenobarbital is not a weaker GABA-A modulator; at therapeutic doses it is a potent enhancer of GABA-A function, and the concern is not inadequate efficacy but excess toxicity potential.
Option C: Option C is incorrect -- phenobarbital and diazepam bind completely different sites; phenobarbital binds transmembrane beta-subunit sites while diazepam binds the alpha/gamma subunit interface.
Option D: Option D is incorrect -- phenobarbital increases duration, not frequency, of channel opening; the mechanism differs fundamentally from benzodiazepines; and the safety concern is pharmacodynamic (direct channel opening), not purely pharmacokinetic.
Option E: Option E is incorrect -- phenobarbital does not simply produce more GABA-A agonism at lower occupancy; the critical distinction is direct channel opening without GABA at supratherapeutic concentrations.
3. A patient receiving a continuous IV infusion of dobutamine for cardiogenic shock develops progressive reduction in hemodynamic response over 48-72 hours despite unchanged infusion rates. Which of the following best explains this tachyphylaxis?
A) Dobutamine is converted to an inactive metabolite by catechol-O-methyltransferase (COMT) in the myocardium -- with prolonged infusion, COMT is progressively induced, accelerating dobutamine inactivation at the receptor site and reducing effective drug concentration despite stable plasma levels
B) Prolonged beta1 activation increases myocardial oxygen consumption to a level exceeding coronary supply -- ischemia-induced membrane disruption reduces the number of functional beta1 receptors by preventing proper receptor folding and membrane insertion
C) Dobutamine infusion produces progressive volume expansion through beta-mediated renal sodium retention, diluting plasma dobutamine concentration and reducing the effective dose delivered to cardiac beta1 receptors
E) Sustained beta1-receptor activation by dobutamine drives GRK-mediated receptor phosphorylation and beta-arrestin recruitment, producing homologous desensitization -- over 48-72 hours, internalization and downregulation of cardiac beta1 receptors reduces the total number of functional receptors available for dobutamine to activate, producing progressive hemodynamic tachyphylaxis that is pharmacodynamic rather than pharmacokinetic in origin
ANSWER: E
Rationale:
Dobutamine tachyphylaxis is a well-recognized clinical pharmacodynamic phenomenon that limits the efficacy of prolonged dobutamine infusions in cardiogenic shock and decompensated heart failure. The mechanism is homologous desensitization through the GRK/beta-arrestin pathway. Sustained dobutamine-mediated beta1 receptor activation continuously drives GRK phosphorylation of the agonist-occupied receptor, beta-arrestin recruitment and G protein uncoupling, and receptor internalization via clathrin-coated vesicles. With 48-72 hours of continuous infusion, a substantial proportion of cardiac beta1 receptors are internalized and some are targeted for lysosomal degradation rather than recycling -- reducing total receptor density. The hemodynamic consequence is progressive reduction in cardiac contractility and heart rate response to dobutamine at unchanged infusion rates. Clinically, this tachyphylaxis limits the utility of chronic dobutamine infusions and is one reason why long-term dobutamine infusions in ambulatory heart failure patients have not improved (and may worsen) outcomes. The tachyphylaxis is pharmacodynamic, not pharmacokinetic -- dobutamine plasma concentrations do not change with infusion duration at a fixed rate.
Option A: Option A is incorrect -- while COMT does metabolize catecholamines including dobutamine, progressive COMT induction producing clinically significant tachyphylaxis is not the established mechanism; the primary cause is receptor downregulation.
Option B: Option B is incorrect -- while ischemia does impair myocardial function, ischemia-induced disruption of beta1 receptor folding is not the established mechanism of dobutamine tachyphylaxis.
Option C: Option C is incorrect -- dobutamine does not produce significant renal sodium retention; its primary action is cardiac beta1 and beta2 stimulation rather than aldosterone-like renal effects.
Option D: Option D is incorrect -- dobutamine tachyphylaxis is pharmacodynamic (receptor downregulation), not pharmacokinetic; hepatic CYP1A2 induction is not the mechanism.
4. A 32-year-old man is given lorazepam 4 mg IV for generalized tonic-clonic seizure with termination of the seizure. The emergency physician explains to students that lorazepam is preferred over diazepam for acute seizure termination despite both being benzodiazepines with identical GABA-A mechanisms. Which of the following correctly explains the pharmacodynamic and pharmacokinetic basis for this preference?
A) Lorazepam was chosen because it binds GABA-A receptors irreversibly -- providing prolonged receptor occupancy that prevents seizure recurrence during the post-ictal period without requiring repeated dosing
B) Lorazepam was chosen because it activates a different GABA-A receptor subtype (alpha2-gamma2 rather than alpha1-gamma2) that is selectively expressed in limbic structures critical for seizure propagation, providing more targeted anticonvulsant activity than diazepam's non-selective alpha1/alpha2 modulation
C) Lorazepam was chosen because it has a smaller volume of distribution (Vd) than diazepam, producing a slower redistribution away from the CNS after IV administration -- diazepam's high lipophilicity causes it to redistribute rapidly from brain to peripheral fat and muscle depots, shortening its clinical duration of action in the CNS despite its long plasma elimination half-life; lorazepam's lower lipophilicity produces a more sustained CNS effect after a single IV dose
D) Lorazepam was chosen because its half-life of 72 hours provides both acute seizure termination and prolonged seizure prophylaxis from a single IV dose, eliminating the need for additional anticonvulsant loading
E) Lorazepam is a GABA-A inverse agonist at lower doses that paradoxically suppresses seizures by reducing excitatory GABAergic neurotransmission in inhibitory interneurons, then switches to positive allosteric modulation at the 4 mg dose used for acute seizure termination
ANSWER: C
Rationale:
Lorazepam and diazepam both enhance GABA-A function through positive allosteric modulation at the alpha/gamma subunit interface -- their pharmacodynamic mechanism at the receptor is essentially identical. The clinical difference in their utility for acute seizure termination is pharmacokinetic, not pharmacodynamic at the receptor level. Diazepam is highly lipophilic (log P approximately 2.8) and rapidly penetrates the CNS after IV injection, producing rapid seizure termination -- this is its advantage. However, diazepam's high lipophilicity also causes rapid redistribution from the brain into peripheral fat and muscle depots. This redistribution shortens the effective clinical duration of CNS action to approximately 15-30 minutes despite diazepam having a long plasma elimination half-life of 20-100 hours (due to active metabolites). Lorazepam is less lipophilic (log P approximately 2.4) and redistributes more slowly from the CNS, producing a more sustained clinical anticonvulsant effect of 6-12 hours from a single IV dose. This prolonged CNS duration of action reduces the need for repeat dosing and makes lorazepam more effective for preventing seizure recurrence after termination.
Option A: Option A is incorrect -- lorazepam binds GABA-A receptors reversibly, not irreversibly; all benzodiazepines are reversible competitive modulators.
Option B: Option B is incorrect -- lorazepam and diazepam both modulate alpha1 and alpha2-containing GABA-A receptors with similar subunit selectivity profiles; the preference is not based on subunit selectivity differences.
Option D: Option D is incorrect -- lorazepam's elimination half-life is approximately 10-20 hours, not 72 hours; while its clinical duration is prolonged compared to diazepam due to lower lipophilicity, the 72-hour figure and the claim of eliminating need for additional anticonvulsants are both incorrect.
Option E: Option E is incorrect -- lorazepam is a positive allosteric modulator at all clinically used doses; it does not exhibit dose-dependent switch from inverse agonism to PAM activity.
5. Memantine is used in moderate-to-severe Alzheimer's disease. Its mechanism involves low-affinity, use-dependent NMDA receptor open-channel block. Why is low affinity (rather than high affinity) pharmacodynamically advantageous for this indication?
A) Low affinity is advantageous because it allows memantine to compete with endogenous glutamate at the orthosteric GluN2 binding site -- high-affinity NMDA blockers would be outcompeted by the high synaptic glutamate concentrations in Alzheimer's disease, rendering them ineffective
B) Low affinity and fast off-rate allow memantine to block pathologically excessive, tonic NMDA receptor activation (driven by elevated ambient glutamate in Alzheimer's disease) while allowing rapid unblocking during normal phasic synaptic transmission; a high-affinity NMDA blocker would remain bound too long after normal synaptic activation, impairing the physiological NMDA-dependent calcium influx required for learning and memory consolidation -- producing a therapeutic paradox of blocking the very process being treated
C) Low affinity reduces memantine's clinical half-life to under 30 minutes, allowing once-daily dosing that avoids the accumulation-related cognitive side effects seen with longer-acting NMDA blockers
D) Low affinity prevents memantine from crossing the blood-brain barrier in concentrations sufficient to block NMDA receptors involved in motor function, providing selective cognitive benefit without motor side effects
E) Low affinity makes memantine a partial agonist at NMDA receptors rather than a full antagonist -- it maintains approximately 50% NMDA receptor activation, preventing both the excitotoxicity of full activation and the cognitive impairment of full blockade
ANSWER: B
Rationale:
The pharmacodynamic elegance of memantine lies in its low receptor affinity combined with use-dependent (open-channel) block. In Alzheimer's disease, dysregulated glutamate signaling produces a state of tonic, low-level NMDA receptor activation from elevated ambient glutamate in the extracellular space. This tonic activation produces a background noise of NMDA-mediated calcium influx that impairs signal detection, contributes to excitotoxic neuronal injury, and may itself desensitize NMDA receptors (reducing their responsiveness to the phasic, high-amplitude glutamate signals associated with learning). Memantine's low affinity and fast off-rate (high koff) mean that it can block the low-level tonic NMDA activation (because the channels are open long enough during tonic stimulation for memantine to enter and maintain block at low concentrations) while being rapidly displaced during the high-amplitude phasic glutamate bursts of normal synaptic transmission (where the large glutamate signal outcompetes memantine's low affinity at the channel pore). This allows memantine to reduce the pathological tonic NMDA noise while preserving the physiological phasic NMDA signaling required for LTP (long-term potentiation) and memory formation. A high-affinity NMDA blocker such as PCP (phencyclidine) or MK-801 (dizocilpine, a high-affinity NMDA channel blocker) would remain bound throughout both tonic and phasic NMDA activation, blocking all NMDA signaling and producing profound cognitive impairment, psychosis, and anesthesia.
Option A: Option A is incorrect -- memantine acts as an open-channel blocker at the channel pore, not at the orthosteric glutamate binding site on GluN2; it does not compete with glutamate for the same binding site.
Option C: Option C is incorrect -- memantine's clinical half-life is approximately 60-80 hours, not 30 minutes; its low affinity refers to receptor binding kinetics, not plasma pharmacokinetics.
Option D: Option D is incorrect -- memantine readily crosses the blood-brain barrier and is not selectively excluded from motor circuits; its selectivity arises from channel state-dependence and kinetics, not anatomical distribution.
Option E: Option E is incorrect -- memantine is a channel blocker (open-channel antagonist), not a partial agonist; partial agonism at NMDA receptors is a distinct pharmacological concept.
6. A patient on chronic opioid therapy for cancer pain is rotated from morphine to hydromorphone after developing severe side effects. He initially experiences improved analgesia at lower-than-expected equianalgesic doses of hydromorphone. Which of the following best explains this pharmacodynamic phenomenon?
A) The mu-opioid receptor adaptations accumulated during chronic morphine exposure -- GRK phosphorylation patterns, beta-arrestin recruitment efficiency, and receptor internalization states -- are partly receptor-specific and partly agonist-conformation dependent; when hydromorphone binds the mu-opioid receptor, it stabilizes a slightly different receptor conformation than morphine, producing a different GRK phosphorylation pattern and less beta-arrestin recruitment relative to its G protein signaling; the receptor adaptations that diminished morphine's efficacy do not fully transfer to hydromorphone, effectively restoring greater analgesic sensitivity at the cellular level
B) Hydromorphone has a higher oral bioavailability than morphine, producing higher plasma concentrations at equivalent doses and explaining the improved analgesia through pharmacokinetic rather than pharmacodynamic mechanisms
C) Hydromorphone is a partial agonist with higher intrinsic efficacy than morphine -- it produces greater G protein activation per receptor occupancy event, overcoming the receptor downregulation accumulated during chronic morphine therapy
D) The initial improvement reflects reversal of morphine-specific mu-receptor downregulation -- hydromorphone binds a different receptor subpopulation (delta-opioid receptors) that was not downregulated during morphine therapy, providing fresh receptor reserve for analgesic signaling
E) Hydromorphone produces less beta-arrestin recruitment than morphine at equivalent doses, directly reducing receptor internalization rate and maintaining higher functional receptor density during the rotation period through a biased agonism mechanism
ANSWER: A
Rationale:
Opioid rotation -- switching from one opioid to another when analgesic efficacy declines or side effects become intolerable -- is a well-established clinical strategy in cancer pain management. The pharmacodynamic basis for the initial analgesic improvement is complex but is best explained by incomplete cross-tolerance. During chronic morphine therapy, the mu-opioid receptor undergoes specific adaptations: GRK-mediated phosphorylation at specific serine/threonine residues, beta-arrestin recruitment and biased signaling states, receptor internalization and partial downregulation, and post-receptor signaling pathway adaptations (adenylyl cyclase supersensitization). These adaptations are partly agonist-specific because different opioid agonists stabilize different receptor conformations, leading to different GRK phosphorylation patterns and different beta-arrestin interaction states. When the receptor encounters a structurally different opioid (hydromorphone vs morphine), the specific receptor conformational adaptations that diminished morphine's G protein coupling efficiency do not fully apply to the new agonist. Hydromorphone effectively encounters a receptor population that has some preserved sensitivity to its specific binding conformation, producing better-than-expected analgesia at the start of rotation. This is incomplete cross-tolerance -- the tolerance that developed to morphine does not fully transfer to hydromorphone. Clinically, this means that hydromorphone should initially be dosed at 50-75% of the calculated equianalgesic dose to avoid overdose during rotation.
Option B: Option B is incorrect -- both morphine and hydromorphone are typically administered parenterally or orally in opioid-tolerant cancer patients; pharmacokinetic bioavailability differences do not explain the receptor-level incomplete cross-tolerance phenomenon.
Option C: Option C is incorrect -- hydromorphone is a full mu-opioid agonist, not a partial agonist; it does not have higher intrinsic efficacy than morphine in the pharmacodynamic sense.
Option D: Option D is incorrect -- hydromorphone primarily acts at mu-opioid receptors, not delta receptors; while it does have some delta activity, this is not the basis of the clinical rotation benefit.
Option E: Option E is incorrect -- while hydromorphone may have some differences in beta-arrestin recruitment compared to morphine, this biased agonism explanation is more speculative than the established incomplete cross-tolerance mechanism.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.